The clinical spectrum of Aspergillus-associated diseases (AAAD) includes -induced asthma, allergic bronchopulmonary (ABPA) and granulomatosis. Corticosteroids almost always used to suppress the response to the fungal antigens.1 there are no evidence-based treatment options besides , the well-known adverse effects of drugs have prompted clinicians to look this standard practice and several of ABPA patients with very positive after omalizumab therapy have recently published.
No takes yet. Share an insight, caveat, or question.
Pérez‐de‐Llano et al. (2011) studied this question.